Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

PREVENT Tool Accurately Predicts HF Risk, With ‘Strong’ ASCVD Overlap

Yael L. Maxwell

December 17, 2024

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

L.A. McKeown

October 23, 2024

News Daily News

ACC/AHA Clarify How Social Determinants of Health Impact CVD

Caitlin E. Cox

August 28, 2024

News Daily News

Scoring System Puts Focus on Medical Therapy Optimization in HFrEF

L.A. McKeown

August 13, 2024

News Daily News

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

L.A. McKeown

May 17, 2024

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

L.A. McKeown

February 23, 2024

News Daily News

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

L.A. McKeown

October 10, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Daily News

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

L.A. McKeown

March 27, 2023

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

L.A. McKeown

February 17, 2023

News Daily News

Vast Majority of HFrEF Patients Eligible for Vericiguat

L.A. McKeown

February 08, 2023

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Daily News

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

Michael O'Riordan

June 16, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

Advertisement

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

PREVENT Tool Accurately Predicts HF Risk, With ‘Strong’ ASCVD Overlap

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

ACC/AHA Clarify How Social Determinants of Health Impact CVD

Scoring System Puts Focus on Medical Therapy Optimization in HFrEF

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

AHA/ACC Scientific Statement Supports Exercise Therapy in HFpEF

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

Vast Majority of HFrEF Patients Eligible for Vericiguat

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content